Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs
For José Baselga, who took over cancer research and development at AstraZeneca after leaving a top job at Memorial Sloan Kettering under a cloud, new data the company is presenting Sunday morning about using its drug Lynparza in pancreatic cancer are a vindication.
